Shuttle Pharma Nears 50% Enrollment in Phase 2 Trial of Ropidoxuridine for Glioblastoma with Promising Tolerability and Completion Rates

Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer pati...

May 09, 2025 | Friday | News
GeneFab and RegCell Unite to Accelerate U.S. Clinical Manufacturing of Next-Gen Treg Therapies

GeneFab, a next-generation cell and gene therapy-focused contract research, development, and manufacturing organization (CRDMO), has partnered with RegCe...

May 08, 2025 | Thursday | News
Moleculin Secures Two New U.S. Patents for Annamycin, Expanding IP Protection Through 2040

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfoli...

May 06, 2025 | Tuesday | News
Australia’s Immutep Achieves 17.6-Month Survival with Chemo-Free Immunotherapy in Head and Neck Cancer

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS...

May 06, 2025 | Tuesday | News
Teva and Alvotech’s SELARSDI™ Approved by FDA as Interchangeable Biosimilar to Stelara®

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentat...

May 06, 2025 | Tuesday | News
Bavarian Nordic Secures UK Approval for VIMKUNYA® Chikungunya Vaccine

Bavarian Nordic A/S announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Ki...

May 05, 2025 | Monday | News
InnoCare’s Zurletrectinib Granted Priority Review in China for NTRK Fusion-Positive Tumors

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new generation...

May 02, 2025 | Friday | News
EU Recommends Approval of Fixed-Duration Calquence Regimen for Untreated Chronic Lymphocytic Leukaemia

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has ...

May 01, 2025 | Thursday | News
Jazz Pharmaceuticals’ Zanidatamab Receives Positive CHMP Opinion for HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adop...

April 28, 2025 | Monday | News
Insmed Announces Landmark Phase 3 ASPEN Study Results Demonstrating Brensocatib’s Breakthrough Potential in Bronchiectasis

Insmed Incorporated, a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patie...

April 24, 2025 | Thursday | News
Argent BioPharma Enters German Market with CannEpil® and CogniCann® Following Regulatory Approval

Argent BioPharma Ltd. , a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into th...

April 24, 2025 | Thursday | News
Dupixent Secures FDA Nod for Chronic Spontaneous Urticaria in Patients Unresponsive to Antihistamines

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,0...

April 21, 2025 | Monday | News
Daiichi Sankyo and AstraZeneca’s ENHERTU Combo Outperforms Standard of Care in First-Line HER2+ Metastatic Breast Cancer

DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU is the first trial in more than a decade to demonstrate superior eff...

April 21, 2025 | Monday | News
Akeso Secures NMPA Approval for Ebdarokimab to Treat Moderate-to-Severe Plaque Psoriasis in Adults

Akeso, Inc. is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from ...

April 21, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close